India will have approved the Covid-19 vaccine by 2021 Q1.

The COVID-19 vaccine in India can be available after the completion of phase 3 clinical trials associated with the Covishield vaccine.

The COVID-19 vaccine in India can be available after the completion of phase 3 clinical trials associated with the Covishield vaccine. The phase III clinical trials of the COVID-19 vaccine, Covishield, was initiated by the Serum Institute of India(SII) in the country that is one of the largest vaccine manufacturers in the world. The SII was opted by AstraZeneca and Oxford University to manufacture the vaccine after the completion of all the trials.

The CEO of Pune based Serum Institute of India, Adar Poonawalla, had claimed that India would have an approved COVID-19 vaccine by December 2020 or in the first quarter of 2021 as the country would start manufacturing 700 million to 800 million doses of vaccine after the trials. Presently, the government has granted the institution permission only to manufacture the vaccine and stockpile it for future use.

However, all the trials of the vaccine are estimated to be completed by May 2021, with phase III trials still in its underway, there is uncertainty on the availability of the vaccine in the first quarter of 2021.

The COVID-19 pandemic has given rise to a lot of potentially dangerous misinformation. For reliable advice on COVID-19 including symptoms, prevention and available treatment, please refer to the World Health Organisation or your national healthcare authority.